Bruno Medeiros
Academic Appointments
- Assistant Professor - Med Center Line, Medicine - Hematology
Contact Information
-
Clinical Offices
Stanford Comprehensive Cancer Center 875 Blake Wilbur Dr CC2329 MC 5821 Stanford, CA 94305 Tel Work (650) 498-5000 Fax (650) 724-5203
Professional Snapshot
Clinical Focus
- Cancer > Hematology
- Hematology
Professional Education
| Board Certification: | Hematology, American Board of Internal Medicine (2006) |
| Board Certification: | Medical Oncology, American Board of Internal Medicine (2005) |
| Fellowship: | University of Colorado Health Science Center, CO (2005) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (2002) |
| Residency: | University of Colorado Health Science Center, CO (2002) |
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information
| Consulting: | Antisoma Inc , Celgene |
Scientific Focus
Research Interests
My clinical activities combine the development of novel therapeutic modalities with the care of patients with multiple malignant hematological disorders. These include acute and chronic leukemias, myelodysplastic syndromes and myeloproliferative disorders.
Clinical Trials
- A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) Recruiting
- An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome Recruiting
- Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting
- Phase I/II Combination 5-azacitidine and Gemtuzimab Ozogamycin for Relapsed AML Recruiting
- Phase I/II of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients with Acute Myeloid Leukemia Recruiting
Publications
- Comparing apples and oranges in normal karyotype acute myeloid leukemia. J Clin Oncol. 2009; (3): 474; author reply 474-6
- Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy. Am J Hematol. 2009; (10): 698-9
- Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009; (17): 1787; author reply 1787-8
- Role of CEBPA in normal karyotype acute myeloid leukemia. J Clin Oncol. 2009; (12): 2105; author reply 2106
Help